FIELD: medicine.
SUBSTANCE: invention relates to immunology and oncology. A method for inducing an immune response to tumour cells in a mammalian body is developed, involving a) detection of differences in gene signatures of tumour and normal cells, including prioritization by level of expression of mutant gene, uniqueness, agretopicity; b) synthesis of a set of DNA templates, each of which contains an open reading frame encoding one of the detected gene signatures or an open reading frame encoding from 2 to 80 detected gene signatures; c) synthesis of a set of mRNA based on the obtained set of DNA templates, wherein the mRNA contains the sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:8 at 5'-end; an open reading frame encoding from 1 to 80 tumour gene signatures; sequence SEQ ID NO: 6 or SEQ ID NO: 7 at 3'-end; d) obtaining lipid nanoparticles containing synthesized mRNA; e) introducing the obtained lipid nanoparticles into the mammalian body.
EFFECT: invention enables the immune system to efficiently detect and destroy tumour cells; invention can be used in therapy of patients with oncological diseases of various aetiologies.
1 cl, 4 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOBIOLOGICAL AGENT FOR THERAPY OF ONCOLOGICAL DISEASES BASED ON mRNA VECTOR | 2024 |
|
RU2828631C1 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCING IMMUNE RESPONSE AGAINST INFLUENZA VIRUS AND USE THEREOF | 2024 |
|
RU2838904C1 |
| PLASMID DNA CARTRIDGE pVAX-C3-polyA, PLASMID DNA MATRIX pVAX-C3-RBD-polyA FOR mRNA SYNTHESIS AND POLYNUCLEOTIDE VACCINE AGAINST SARS-CoV-2, WHICH IS MOLECULES mRNA-C3-RBD-polyA WHICH INDUCE SARS-CoV-2-SPECIFIC ANTIBODIES | 2024 |
|
RU2839841C1 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCING A COMPLEX IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS AND INFLUENZA VIRUS AND USE THEREOF | 2024 |
|
RU2836687C1 |
| PLASMID FOR EXPRESSION OF RECOMBINANT HUMAN CHORIONIC GONADOTROPIN (HCG), PLASMID FOR EXPRESSION OF RECOMBINANT ALPHA- AND BETA-SUBUNITS OF HCG, MONOCLONAL LINE OF MAMMALIAN CELLS - PRODUCER OF HCG, METHOD OF PRODUCING RECOMBINANT HCG | 2024 |
|
RU2834784C1 |
| LINE OF GENETICALLY MODIFIED MICE FOR SIMULATING ALZHEIMER'S DISEASE, METHOD FOR PRODUCTION THEREOF AND ITS USE, sgRNA AND COMBINATION OF crRNA/tracRRNA USED IN THE METHOD, AND A SET OF PRIMERS | 2024 |
|
RU2835497C1 |
| MONOCLONAL ANTIBODIES SPECIFIC TO PROTEIN RUSTICYANIN, AND USE OF ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS | 2024 |
|
RU2823344C1 |
| mRNA-BASED VECTOR FOR INCREASED TARGET PROTEIN PRODUCTION IN MAMMALIAN CELLS (VARIANTS) | 2022 |
|
RU2792231C1 |
| METHOD OF PRODUCING MOUSE MODEL FOR STUDYING DUCHENNE MUSCULAR DYSTROPHY AND VERSIONS OF ITS THERAPY | 2023 |
|
RU2815936C1 |
| PLASMID DNA MATRIX AND mRNA MOLECULE USED TO PRODUCE VACCINE AGAINST CORONAVIRUS, OBTAINED USING DNA MATRIX AND PROVIDING EXPRESSION OF GENE OF ARTIFICIAL POLYEPITOPIC PROTEIN-IMMUNOGEN CONTAINING CONSERVED EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC IMMUNITY | 2024 |
|
RU2839372C1 |
